Navigation Links
Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division
Date:3/3/2015

LAKE FOREST, Calif., March 3, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced the expansion of its relationship with Fred Hutchinson Cancer Research Centers' ("Fred Hutch") Clinical Research Division with the inclusion of additional labs to be supported by Cryoport's validated cryogenic logistics solutions for its cell-based therapies.

The Clinical Research Division at Fred Hutch has teams of investigators who conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a wide variety of disciplines, their clinical researchers are continually developing new therapeutic approaches and leading clinical trials that will help drive discoveries from the laboratory to the patient. Fred Hutch's pioneering research has saved countless lives. 

Cryoport is working with the dedicated researchers at Fred Hutch to support access of their crucial research to the scientific and patient communities, specifically supporting cord blood transplants and clinical research and trials for cell-based therapies.

"Cryogenic transport is a key element in the distribution for some of our experimental therapies to the scientific community, said Shelly Heimfeld, Ph.D., researcher in the Clinical Research Division at Fred Hutch. Working with Cryoport has enabled us to focus on the complexities that surround our work while depending on Cryoport to handle the logistical challenges that we encounter with transport of cryopreserved products." 

Jerrell Shelton, Cryoport's CEO, stated, "Fred Hutch is a world-renowned research organization respected throughout the life sciences community. It is an honor to work with an organization that has been dedicated to critical lifesaving research for over 40 years.  Fred Hutch's pioneering research has established a legacy of innovation and excellence and Cryoport is delighted to expand its support of these important endeavors with our unrivaled validated cryogenic logistics solutions for the life sciences industry.  It is a continuing pleasure to have our strong working relationship with the Fred Hutchinson team."

About Cryoport, Inc.

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit www.cryoport.com.

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or  Android mobile device.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


'/>"/>
SOURCE Cryoport, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology news :

1. DRI expands Chinese partnership to address water pollution, management issues
2. Hartman Foundation expands support for co-op program
3. Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris
4. Millennium Laboratories Expands Pharmacogenetic Test to Help Clinicians Prescribe the Right Medicine at the Right Dose
5. DigitalPersona Expands Secure Banking Solutions Portfolio with Software Acquisition
6. BioForce Nanosciences, Inc. Expands Its Global Market. New partnership with Acugenex Limited
7. The DOE Joint Genome Institute expands capabilities via new partnerships
8. CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation
9. CLEAR Supports TSAs Goal of Strengthening Airport Security
10. Jeffrey Modell Foundation supports Belgian research on primary immunodeficiency
11. Neurotropes Approach to Treating Alzheimers Disease Through Its Product Bryostatin-1, an Activator of Protein Kinase C Epsilon (PKCe), Supported by Blanchette Rockefeller Neurosciences Institute (BRNI) Publication, Identifying PKCe as a Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology: